Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NYMXF Alzheimer's treatment! -- Ignore unavailable to you. Want to Upgrade?

To: Ron who wrote (108)	7/24/1998 9:48:00 AM
From: Demetre Deliyanakis	Read Replies (1) \| Respond to of 132

Here are my 2 cents worth on Nymox. Before I continue, I should disclose that I am a shareholder of the company. I am debating whether to sell my shares in the company. In my opinion, the recent fall in Nymox's share price can be attributed to the following events. 1. The company has not announced when the urine test will be available. 2. The service fees reported in the 1st quarter were only $4,000 Canadian. Given that the company charges $400 U.S. for the spinal test, it looks like only 7 tests were paid for . This is very low considering the peer reviewed study that was released in December 1997. However, it may be that the test is being given away in order to encourage doctors to try the test. Hopefully, Nymox will release information to show how many tests were sold or given away. IMHO, a key piece of information will be the second quarter's service fee revenues. Nymox received much publicity after its March news release. Will the publicity translate into revenue? In May 1997, the company announced that they had signed an agreement with Multiplan , a large preferred provider in the U.S. They claim to have over 20 million patients enrolled in their health plan. I assume that this meant that Multiplan would pay for the nymox test. However,given the level of service fees reported to date, I wonder if Multiplan still supports the test. I think that the company will eventually have to enter into an agreement with a major drug company in order to better market the test. I would welcome any reactions to my comments.